Tin tức & Cập nhật

Researchers from the Chinese University of Hong Kong (CUHK) have conducted the world’s first study to show that nightly use of low-concentration (0.05 percent) atropine eye drops may reduce the incidence of myopia in high-risk children.

Use of ranibizumab and lower-dose bevacizumab results in a higher rate of retreatment as compared with higher-dose bevacizumab use in patients with retinopathy of prematurity (ROP) initially treated with antivascular endothelial growth factors (anti-VEGFs), a study has shown.

New drug applications approved by US FDA as of 16-28 February 2023 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Nightly use of 0.05% atropine eye drops among children appears to lead to a significantly lower incidence of near-sightedness, as shown in the results of the LAMP2 study from Hong Kong.

Treatment with repeated low-level red-light (RLRL) therapy with 100-percent power results in significant reduction in myopia progression over 6 months in myopic children when compared to a sham device with 10-percent original power, a China study has shown. In addition, the RLRL therapy is well tolerated and does not lead to serious adverse effects (AEs)